Celgene is a biopharmaceutical company that discovers, develops and commercialises innovative therapies for the treatment of cancer and other serious inflammatory diseases. Celgene is a medium-sized company which invests double the pharmaceutical industry average into scientific research, driving clinical advances in fatal and rare diseases, and diseases with the biggest unmet medical need, to develop medicines that bring value to healthcare systems.
Celgene has been operating in Portugal since 2007, currently, employing 17 people dedicated to marketing and sales operations, and medical education. One third of employees focus exclusively on medical and clinical research, covering five main areas of activity: regulatory and safety, market access, clinical research, external and public relations, and medical education.
- Celgene Portugal is committed to support local institutions’ capacity to participate either in international clinical trials from Celgene’s global programme established in the EU or the academic investigator-initiated trials.
- At the moment there are ten Celgene sponsored CT ongoing and feasibility processes for new trials under review and four ongoing academic CT with financial support from Celgene.
- Since the beginning of their operations in Portugal, close to 100 patients have been treated in Celgene sponsored CT and academic CT.
- Revlimid and Vidaza, both Orphan drugs for few patients and for real unmet medical needs, have been proven evidence of therapeutic value and effectiveness, demonstrating OS and real benefits for patients with threaten-life diseases.
Celgene Portugal collaborates with most of existing hematologic and oncologic associations in Portugal contributing to their initiatives to support the patients and careers; namely, fund-raising, educational sessions about the disease, and the rights of the patients.
Celgene Portugal is committed not only to provide up-to-date information on the management of the diseases, but essentially to support a local platform for the existing three hematologic associations in Portugal and facilitating networking with the European counterparts as well. This will allow patient groups to share best practice in patient advocacy and become better equipped to support the patients and careers who use their services, optimizing resources and broad coverage of supporting patients in Portugal independent of their local of living.